BerGenBio AS
BerGenBio AS is a biotech company that focuses on research and development of novel cancer drug targets and the clinical development of first in class drugs. Visit official website of BerGenBio AS to learn more about one of the most exciting research and development in the field of cancer today.
NORWEGIAN MEDIA COVERAGE
17.01.2012 Bergens Tidende: “Morgendagens kunnskpsbedrifter er blant de første som dør i økonomiske krisetider. De er for risikable, så alle forlater dem”
09.01.2012 Dagens Næringsliv “Får 50 mill. til å hemme kreftgener”
09.01.2012 Investinor: “Ny investering i bioteknologi”
16.03.2011 Bergens Tidende: “Pris til kreftjeger”
10.02.2011 Bergens Tidende: “Jakter gener i kampen mor kreft”
18.09.2010 Finansavisen: ”30 millioner til kreftceller”
INTERNATIONAL MEDIA COVERAGE
12.01.2012 Eurotech: “Norwegian BerGenBio gets Series A financing for cancer candidates”
09.01.2012 Genengnews: “BerGenBio raises $8.8M to Advance Axl Kinase Inhibitor Drug Into Clinical Trials”
09.01.2012 Finsmes:“BerGenBio Completes $8,8M Series A Financing”
04.01.2012 Argentum: “BerGenBio attracts funding”
31.10.2011 News Medical: “BerGenBio commences of principal developmen of BgB-324 anti-cancer drug”
20.05.2009 Outsourcing-Pharma: “BerGenBio RNAi services attract biotech”